CCL4 and type 2 diabetes mellitus: The levels of inflammatory markers, such as TNF-α and IL-6, which are the root causes of insulin resistance in type 2 diabetic patients with type 2 diabetes, were decreased in the CCL4 antibody injection group, compared with those in the IgG-treated DM group (Figure 3D).